Paula Mello De Luca
Overview
Explore the profile of Paula Mello De Luca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira-Paes T, Gervazoni L, Seixas-Costa P, De Luca P, Almeida-Amaral E
Nutrients
. 2025 Mar;
17(5).
PMID: 40077719
Background/objectives: Malnutrition and visceral leishmaniasis are major public health problems that are responsible for millions of deaths across many countries. Leishmaniasis development and progression are associated with the host immune...
2.
Lanna M, Resende L, De Luca P, Goes W, Zaldivar M, Costa A, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39771984
Background/objectives: Considering the large number of candidates in vaccine-testing studies against different pathogens and the amount of time spent in the preclinical and clinical trials, there is a pressing need...
3.
Conceicao Silva F, De Luca P, Lima-Junior J
Vaccines (Basel)
. 2023 Nov;
11(11).
PMID: 38005964
In the 18th century, English physician Edward Jenner laid the foundation for modern vaccination by achieving protection against variola [...].
4.
Cajaraville A, Gomes M, Azamor T, Pereira R, Neves P, De Luca P, et al.
Vaccines (Basel)
. 2023 Jan;
11(1).
PMID: 36679918
The attenuated yellow fever (YF) vaccine is one of the most successful vaccines ever developed. After a single dose administration YF vaccine can induce balanced Th1/Th2 immune responses and long-lasting...
5.
Conceicao-Silva F, Reis C, De Luca P, Leite-Silva J, Santiago M, Morrot A, et al.
Cells
. 2021 Aug;
10(8).
PMID: 34440659
The first formal description of the microbicidal activity of extracellular traps (ETs) containing DNA occurred in neutrophils in 2004. Since then, ETs have been identified in different populations of cells...
6.
Arcanjo A, Pinto K, Logullo J, Leite P, Barreto Menezes C, Freire-de-Lima L, et al.
J Infect Dis
. 2021 Aug;
224(10):1672-1683.
PMID: 34427670
Background: Coronavirus disease 2019 (COVID-19) can progress to severe pneumonia with respiratory failure and is aggravated by the deregulation of the immune system causing an excessive inflammation including the cytokine...
7.
Campos M, Figueiredo F, Morgado F, Renzetti A, de Souza S, Pereira S, et al.
Front Immunol
. 2018 Oct;
9:2245.
PMID: 30349528
[This corrects the article DOI: 10.3389/fimmu.2018.01690.].
8.
Campos M, Figueiredo F, Morgado F, Renzetti A, de Souza S, Pereira S, et al.
Front Immunol
. 2018 Aug;
9:1690.
PMID: 30090101
In Brazil, canine visceral leishmaniasis (CVL) is caused by Leishmania infantum, presenting a broad spectrum of clinical manifestations. Dogs are the main parasite reservoir in urban areas and canine cases...
9.
Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis
Santos M, Nico D, de Oliveira F, Barreto A, Palatnik-de-Sousa I, Carrillo E, et al.
Front Immunol
. 2017 Mar;
8:227.
PMID: 28321221
Development of immunoprotection against visceral leishmaniasis (VL) focused on the identification of antigens capable of inducing a Th1 immune response. Alternatively, antigens targeting the CD8 and T-regulatory responses are also...
10.
De Luca P, Macedo A
Front Immunol
. 2016 May;
7:151.
PMID: 27148270
There have been exhaustive efforts to develop an efficient vaccine against leishmaniasis. Factors like host and parasite genetic characteristics, virulence, epidemiological scenarios, and, mainly, diverse immune responses triggered by Leishmania...